A new drug to treat diabetic kidney disease? Taubman Scholar Dr. Frank Brosius partners in clincial trial
With almost 2 million new cases diagnosed each year, more than 8% of the U.S. population has diabetes. And roughly 30% will eventually develop diabetic kidney disease.
Researchers at the University of Michigan Medical School are partnering with Eli Lilly and Company in using a human genome-wide data set, together with mouse models, to identify a key driver of diabetic kidney disease.
Sponsored by Lilly, a new clinical study will examine whether a drug being developed to treat arthritis and skin diseases can be repurposed to help prevent progression of diabetic kidney disease. It takes advantage of genome-wide expression data analyzed by Matthias Kretzler, M.D., Frank Brosius, M.D. and their teams, as well as the investigators’ expertise in animal models of diabetic complications.
"We prioritized this pathway as the most relevant in diabetic nephropathy," said Kretzler. "Together with data from model systems published, there was such strong evidence that Lilly repurposed their compound and started a phase II trial in less than 15 months. It’s exciting because this kind of collaboration between industry and academia is exactly the way we can accelerate new therapies to help patients."
Kretzler is widely recognized for international multicenter studies of genome-wide expression profiles of major diseases affecting human kidneys including diabetes, hypertension and autoimmune diseases like lupus.
"Dr. Kretzler put together a network of research teams to establish a worldwide human genome-wide renal gene expression consortium,” noted Brosius, whose lab is one of 12 organizations participating in the NIH-sponsored Animal Models of Diabetic Complications Consortium. "Then my group provided the animal model studies and the in-depth understanding of diabetic complications that allowed us to focus on the pathway. This highly collaborative approach makes the U-M one of the only places in the world with the combined expertise to move this project forward."
10 Taubman Scholars named to "Best Doctors in America" list
They're among 493 U-M physicians to receive the honor from their peers
Click here for the list.
People who care
ALS Association Michigan Chapter honors institute
Founder A. Alfred Taubman and Director Dr. Eva Feldman to receive inaugural award at April 3 gala
Click here for details
U-M offers new early detection prostate cancer test
Research by Taubman Scholar Dr. Arul Chinnaiyan has let to the development of a new test for prostate cancer that is far more accurate than the standard PSA test, the University of Michigan has announced.
Click here to read more.
news & events
New Taubman Prize trophy debuts
The new trophy for the Taubman Prize for Excellence in Translational Medical Research, which was designed in consultation with institute founder Mr. A. Alfred Taubman, was presented at the institute's Oct. 11 symposium. The modern sculpture was created using a novel 3D printing technique.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.